HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
University of California, San Francisco
San Francisco, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California, San Francisco (16)
2022
-
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
Life science alliance, Vol. 5, Núm. 4
2021
-
Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism
American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150
-
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained
Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243
2020
-
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682
2019
-
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642
-
Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita
Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285
-
Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Journal of Bone and Mineral Research
2018
2017
-
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication
Heart Rhythm, Vol. 14, Núm. 1, pp. e3-e40
-
Metabolomic signatures associated with disease severity in multiple sclerosis
Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, Núm. 2
-
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594
2016
-
EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication
Journal of Arrhythmia, Vol. 32, Núm. 4, pp. 247-278
-
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication
Europace, Vol. 18, Núm. 10, pp. 1455-1490
2013
-
Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6
PLoS ONE, Vol. 8, Núm. 4
-
Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial
Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649
2012
-
A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis
Genes and Immunity, Vol. 13, Núm. 1, pp. 21-28